{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T03:40:03Z","timestamp":1767066003325,"version":"3.38.0"},"reference-count":0,"publisher":"University of Toronto Press Inc. (UTPress)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical and Investigative Medicine"],"published-print":{"date-parts":[[2012,4,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> The guidelines for management of prolactinomas during pregnancy are mostly based on retrospective evidence or expert opinion. We conducted a survey to assess the current trends in management of prolactinomas during pregnancy. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p> A case-based electronic questionnaire was sent in January 2011 to all practicing endocrinologists, in four Canadian provinces: Nova Scotia, New Brunswick, Prince Edward Island and British Columbia with three cases of varying severity; ranging from a microprolactinomas to a large macroprolactinomas compressing the optic chiasm. <\/jats:p><\/jats:sec><jats:sec><jats:title>Result<\/jats:title><jats:p> There was a considerable diversity among endocrinologists with regards to monitoring and managing prolactinomas during pregnancy. In case of microprolactinomas, 94% of specialists would discontinue dopamine agonist (DA) therapy upon confirmation of pregnancy, 79% would discontinue serum prolactin measurement during pregnancy, and 94% would not perform routine pituitary imaging in the absence of new symptoms whereas 32% would perform regular formal visual field (VF) testing throughout pregnancy. In the case of macroprolactinomas, 65% chose to discontinue DA therapy upon confirmation of pregnancy, 30% would either perform regular MRI during pregnancy or, if serum prolactin was thought to be elevated out of proportion, with clinical judgment and 40% would not perform regular formal VF monitoring during pregnancy. In management of large macroprolactinomas, 82% elected to continue DA therapy whereas 18% chose surgical excision as the treatment of choice. Forty nine percent would perform regular MRI during pregnancy and 94% would perform regular formal VF monitoring during pregnancy. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Among endocrinologists there is considerable diversity in management of prolactinomas during pregnancy, indicating a need for better consensus and clearer guidelines. <\/jats:p><\/jats:sec>","DOI":"10.25011\/cim.v35i2.16293","type":"journal-article","created":{"date-parts":[[2017,5,2]],"date-time":"2017-05-02T23:16:05Z","timestamp":1493766965000},"page":"E96-E104","source":"Crossref","is-referenced-by-count":11,"title":["Management of prolactinomas during pregnancy \u2013 A survey of four Canadian provinces"],"prefix":"10.3138","volume":"35","author":[{"given":"Mussa H","family":"Almalki","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism, University of British Columbia, Vancouver, British Columbia, Canada."},{"name":"Diabetes Center, King Fahad Medical City, Riyadh, Saudi Arabia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehud","family":"Ur","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, University of British Columbia, Vancouver, British Columbia, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Johnson","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, University of British Columbia, Vancouver, British Columbia, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David B","family":"Clarke","sequence":"additional","affiliation":[{"name":"Divisions of Neurosurgery and Endocrinology and Metabolism, Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed A","family":"Imran","sequence":"additional","affiliation":[{"name":"Divisions of Neurosurgery and Endocrinology and Metabolism, Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1696","container-title":["Clinical and Investigative Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/cimonline.ca\/index.php\/cim\/article\/viewFile\/16293\/13256","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/utppublishing.com\/doi\/pdf\/10.25011\/cim.v35i2.16293","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T18:30:28Z","timestamp":1741890628000},"score":1,"resource":{"primary":{"URL":"https:\/\/utppublishing.com\/doi\/10.25011\/cim.v35i2.16293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,1]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4,1]]}},"alternative-id":["10.25011\/cim.v35i2.16293"],"URL":"https:\/\/doi.org\/10.25011\/cim.v35i2.16293","relation":{},"ISSN":["1488-2353"],"issn-type":[{"type":"electronic","value":"1488-2353"}],"subject":[],"published":{"date-parts":[[2012,4,1]]}}}